ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
0.7549
+0.0594 (8.54%)
At close: Apr 1, 2025, 4:00 PM
0.7028
-0.0522 (-6.91%)
After-hours: Apr 1, 2025, 4:21 PM EDT

Company Description

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.

The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.

ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciences, Inc.
ProMIS Neurosciences logo
Country Canada
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Neil K. Warma

Contact Details

Address:
1920 Yonge Street, Suite 200
Toronto, ON M4S 3E2
Canada
Phone 416 847 6898
Website promisneurosciences.com

Stock Details

Ticker Symbol PMN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001374339
CUSIP Number 74346M406
ISIN Number CA74346M4065
SIC Code 2834

Key Executives

Name Position
Neil K. Warma M.B.A. Chief Executive Officer, President and Director
Eugene W. Williams Co-Founder and Chairman
Dr. Neil R. Cashman M.D. Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director
Daniel E. Geffken M.B.A. Chief Financial Officer
Dr. Johanne Kaplan Ph.D. Chief Development Officer
Dr. David Wishart Ph.D. Chief Physics Officer
Dennis Chen Ph.D. Head of Manufacturing and Senior Consultant
Dr. Larry Douglas Altstiel M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 424B5 Filing
Mar 31, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 19, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 27, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report
Jan 8, 2025 8-K Current Report